Navigation Links
Alma Lasers Announces FDA Clearance of the Harmony(XL) Multi-Application System at THE Aesthetic Show 2008
Date:5/29/2008

Harmony(XL) handpiece is designed for maximum effectiveness with minimal patient discomfort. One of the most popular options is the Laser360(TM) skin rejuvenation treatment. The new procedure uses three handpieces from the Harmony(XL) system to treat a wide range of age and photo-damage symptoms. Patients can achieve outstanding results in just 60 days, with minimal or no downtime.

"To give patients a complete treatment, oftentimes physicians need two, three or four different lasers, but with the Harmony(XL) you have one platform with different handpieces, taking the place of larger devices. You can start with one handpiece, treat, and then quickly and easily switch to a different one," said Dr. Stuart Melnick, Medical Director, Laser and Cosmetic Center in Los Gatos, CA.

About Alma Lasers

Alma Lasers is a global medical technology company that designs, develops, manufactures and markets laser, intense pulsed light and radiofrequency based aesthetic treatment devices that can be used to treat a broad range of skin types and indications. Alma Lasers believes that its products have typically been at the forefront of technological development in the energy-based aesthetic treatment system market. Since commercializing its first aesthetic treatment system in 2002, Alma Lasers has introduced multiple systems that work in combination with more than 25 handpieces. Alma Lasers' mission is to leverage its technical expertise and in-depth understanding of practitioners' needs in order to provide modular, cost-effective and high performance designs that enable medical practitioners to confidently offer safe, effective and profitable aesthetic treatments to their patients.

Alma Lasers. Wellbeing Through Technology.


'/>"/>
SOURCE Alma Lasers
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Lumenis Sues Alma Lasers and its 4 founders for 200 Million Shekels
2. Alma(TM) Lasers to Debut Five New Products at the 66th Annual Meeting of the American Academy of Dermatology
3. Alma Lasers Announces Proposed Initial Public Offering
4. Alma Lasers Answers Lumenis Complaint
5. Darwin Announces Creation of New Health Care and Errors and Omissions Divisions
6. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
7. Ekahau Announces Compatibility With 802.11n
8. Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (terlipressin) for the Treatment of Hepatorenal Syndrome Type 1
9. DRAXIS Announces Completion of Sale to Jubilant
10. WellPoint Announces Realignment of Operations, Technology and Government Services Unit
11. Hill-Rom Announces Third Quarter 2008 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 1U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 2U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 3U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 4U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 5West to Present at Two Upcoming Investor Conferences 56960 1West to Present at Two Upcoming Investor Conferences 56960 2Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 1Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 2